FDA rejects Disc's rare disease drug despite commissioner's voucher Read more →

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments Read more →

After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio Read more →